Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Waldenstrom Macroglobulinemia
Related studies linked through entity extraction aliases.
APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE1
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
- Status
- COMPLETED
- Phase
- PHASE2
Dasatinib In Waldenström Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE1
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)
- Status
- COMPLETED
- Phase
- PHASE4
The Registry of Oncology Outcomes Associated with Testing and Treatment
- Status
- COMPLETED
- Phase
- N/A
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
- Status
- COMPLETED
- Phase
- PHASE1
Rifaximin in Patients With Monoclonal Gammopathy
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1
- Status
- UNKNOWN
- Phase
- PHASE2
Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
- Status
- TERMINATED
- Phase
- PHASE1
Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS
- Status
- COMPLETED
- Phase
- N/A